Compare CX & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CX | ICLR |
|---|---|---|
| Founded | 1906 | 1990 |
| Country | Mexico | Ireland |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 13.1B |
| IPO Year | 2000 | 2001 |
| Metric | CX | ICLR |
|---|---|---|
| Price | $9.42 | $161.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $14.81 | ★ $185.82 |
| AVG Volume (30 Days) | ★ 6.1M | 967.5K |
| Earning Date | 10-26-2026 | 10-21-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.01 | N/A |
| Revenue Next Year | $3.61 | $3.69 |
| P/E Ratio | $19.03 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.93 | $66.57 |
| 52 Week High | $13.67 | $203.91 |
| Indicator | CX | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 49.06 |
| Support Level | N/A | $162.32 |
| Resistance Level | $13.30 | $180.07 |
| Average True Range (ATR) | 0.25 | 6.07 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 0.85 | 33.62 |
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.